Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrous Acid SCHEMBL29147932 | 0.93 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6869717 | 0.84 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL56204 | 0.84 | TPMT (0.56) | TPMTTSHRALOX15HIF1ATTR | |
| SCHEMBL23413328 | 0.83 | LMNA (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL2264628 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL27653766 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL11071500 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL7828838 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL27653711 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL27673705 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250145731-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | REMEGEN CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12195552-B2 | Linker for antibody-drug conjugates and its use | REMEGEN CO., LTD. (CN) | 2025-01-14 | — | — | US | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3868409-B1 | THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS | REMEGEN CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3102572-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-12-14 | — | — | EP | disclosed |
| CN-104080791-B | The method separated and use (the fluoro-3-of the chloro-2-of 4-substituted-phenyl) borate | 陶氏益农公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC | 2016-12-01 | — | — | US | disclosed |
| CN-105980378-A | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2015118057-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | WO | disclosed |
| CN-104619707-A | Condensed ring heterocyclic compound | KYOWA HAKKO KIRIN CO LTD | 2015-05-13 | — | — | CN | disclosed |
| CN-104080791-A | Methods of isolating (4-chloro-2-fluoro-3-substituted-phenyl) boronates and methods of using the same | DOW AGROSCIENCES LLC | 2014-10-01 | — | — | CN | disclosed |
| WO-2012035055-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035055-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011110575-A1 | DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | GABRP 798/4885GABRD 2091/4885GABRA1 2018/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | GABRP 798/4885GABRD 2091/4885GABRA1 2018/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | GABRP 731/4885GABRD 2977/4885GABRA1 2097/4885 |
| US-12195552-B2 | Linker for antibody-drug conjugates and its use | PA2G4, IGSF11, FCGRT | GABRP 1364/4885GABRD 663/4885GABRA1 641/4885 |
| US-20250145731-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | PA2G4, IGSF11, FCGRT | GABRP 1364/4885GABRD 663/4885GABRA1 641/4885 |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | GABRP 2295/4885GABRD 3343/4885GABRA1 1712/4885 |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, SRR, RRP12 | GABRP 3021/4885GABRD 3912/4885GABRA1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.